Karen L. Smith - Nov 8, 2024 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Role
Director
Signature
/s/ Karen L. Smith
Stock symbol
AUPH
Transactions as of
Nov 8, 2024
Transactions value $
-$44,182
Form type
4
Date filed
11/12/2024, 07:20 PM
Previous filing
Oct 30, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUPH Common Stock Options Exercise +17.9K 17.9K Nov 8, 2024 Direct F1
transaction AUPH Common Stock Sale -$44.2K -5.24K -29.26% $8.43 12.7K Nov 11, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AUPH Restricted Stock Units Options Exercise $0 -17.9K -100% $0.00 0 Nov 8, 2024 Common Stock 17.9K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2 Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs.
F3 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.37 to $8.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F4 The RSUs vested one year from date of grant and have no expiration date.